WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Completed

Conditions studied: Obesity & Overweight

In brief

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Key facts

Study ID

NCT07216651

Run by

Closed Loop Medicine

People needed

20

Starts

2025-09-23

Expected to finish

2026-03-18

Last updated by the study team

2026-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be 18 years or older.
• Participants must have a diagnosis of either obesity or overweight.
• Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
• Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
• Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.

You may not qualify if…

• Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
• Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.

Where it is running

• Amarillo Premier Research (an Objective Health Partnership) — Amarillo, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.